Ads
related to: abbvie
Search results
(ABBV) - Analyzing AbbVie's Short Interest - AbbVie (NYSE:ABBV)
Benzinga· 12 hours agoAbbVie's ABBV short percent of float has risen 4.05% since its last report. Based on its trading volume, it would take traders 2.43 days to cover their short positions on ...
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
Motley Fool via Yahoo Finance· 17 hours agoThree stocks that you'll want to consider for your portfolio if you're a retiree craving some...
AbbVie Stock Poised for New All-Time Highs in 2024 | Investing.com
Investing.com· 3 days agoAbbVie had a better-than-expected quarter and guided higher; the post-release price drop is a dip...
3 Reasons to Buy AbbVie Stock on the Dip
Motley Fool via Yahoo Finance· 6 days agoIt's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this...
AbbVie to Present at the Bank of America Securities Healthcare Conference
FOX 4 Kansas City· 5 days agoReents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical ...
Keeping an Eye on Abbvie Inc
Knox Daily· 4 days agoAbbvie Inc’s recently made public that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24. In the deal valued ...
ABBV34 | AbbVie Inc Stock Price - Investing.com PH
Investing.com· 5 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts
GuruFocus.com via Yahoo Finance· 12 hours agoThe company's ongoing collaborations, like those with AbbVie on ABBV-RGX-314 for retinal diseases,...
Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates
Zacks· 1 day agoThe top line decreased almost 28% year over year due to a $30.0 million gross-to-net change in estimate for the sole marketed drug, Linzess (linaclotide), recorded to collaborative arrangements ...
Earnings call: Ironwood Pharmaceuticals reports robust Q1 growth
Investing.com· 1 day agoIronwood Pharmaceuticals, Inc. ( NASDAQ : IRWD) provided an update on its financial and operational...